260 related articles for article (PubMed ID: 7931489)
1. Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia.
Rowinsky EK; Adjei A; Donehower RC; Gore SD; Jones RJ; Burke PJ; Cheng YC; Grochow LB; Kaufmann SH
J Clin Oncol; 1994 Oct; 12(10):2193-203. PubMed ID: 7931489
[TBL] [Abstract][Full Text] [Related]
2. A phase I and pharmacological study of topotecan infused over 30 minutes for five days in patients with refractory acute leukemia.
Rowinsky EK; Kaufmann SH; Baker SD; Miller CB; Sartorius SE; Bowling MK; Chen TL; Donehower RC; Gore SD
Clin Cancer Res; 1996 Dec; 2(12):1921-30. PubMed ID: 9816150
[TBL] [Abstract][Full Text] [Related]
3. Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumors.
Rowinsky EK; Grochow LB; Sartorius SE; Bowling MK; Kaufmann SH; Peereboom D; Donehower RC
J Clin Oncol; 1996 Apr; 14(4):1224-35. PubMed ID: 8648378
[TBL] [Abstract][Full Text] [Related]
4. Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue.
Hendricks CB; Rowinsky EK; Grochow LB; Donehower RC; Kaufmann SH
Cancer Res; 1992 Apr; 52(8):2268-78. PubMed ID: 1348448
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of Topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia.
Kantarjian HM; Beran M; Ellis A; Zwelling L; O'Brien S; Cazenave L; Koller C; Rios MB; Plunkett W; Keating MJ
Blood; 1993 Mar; 81(5):1146-51. PubMed ID: 8382970
[TBL] [Abstract][Full Text] [Related]
6. A phase I and translational study of sequential administration of the topoisomerase I and II inhibitors topotecan and etoposide.
Hammond LA; Eckardt JR; Ganapathi R; Burris HA; Rodriguez GA; Eckhardt SG; Rothenberg ML; Weiss GR; Kuhn JG; Hodges S; Von Hoff DD; Rowinsky EK
Clin Cancer Res; 1998 Jun; 4(6):1459-67. PubMed ID: 9626463
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial of sequential topotecan followed by etoposide in adults with myeloid leukemia: a National Cancer Institute of Canada Clinical Trials Group Study.
Crump M; Lipton J; Hedley D; Sutton D; Shepherd F; Minden M; Stewart K; Beare S; Eisenhauer E
Leukemia; 1999 Mar; 13(3):343-7. PubMed ID: 10086724
[TBL] [Abstract][Full Text] [Related]
8. A phase II "window" study of topotecan in untreated patients with high risk adult acute lymphoblastic leukemia.
Gore SD; Rowinsky EK; Miller CB; Griffin C; Chen TL; Borowitz M; Donehower RC; Burks KL; Armstrong DK; Burke PJ; Grever MR; Kaufmann SH
Clin Cancer Res; 1998 Nov; 4(11):2677-89. PubMed ID: 9829730
[TBL] [Abstract][Full Text] [Related]
9. High-dose topotecan with granulocyte-colony stimulating factor in fluoropyrimidine-refractory colorectal cancer: a phase II and pharmacodynamic study.
Rowinsky EK; Baker SD; Burks K; O'Reilly S; Donehower RC; Grochow LB
Ann Oncol; 1998 Feb; 9(2):173-80. PubMed ID: 9553662
[TBL] [Abstract][Full Text] [Related]
10. Altered formation of topotecan-stabilized topoisomerase I-DNA adducts in human leukemia cells.
Kaufmann SH; Svingen PA; Gore SD; Armstrong DK; Cheng YC; Rowinsky EK
Blood; 1997 Mar; 89(6):2098-104. PubMed ID: 9058732
[TBL] [Abstract][Full Text] [Related]
11. Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence.
Rowinsky EK; Kaufmann SH; Baker SD; Grochow LB; Chen TL; Peereboom D; Bowling MK; Sartorius SE; Ettinger DS; Forastiere AA; Donehower RC
J Clin Oncol; 1996 Dec; 14(12):3074-84. PubMed ID: 8955652
[TBL] [Abstract][Full Text] [Related]
12. Topoisomerase II levels and drug sensitivity in adult acute myelogenous leukemia.
Kaufmann SH; Karp JE; Jones RJ; Miller CB; Schneider E; Zwelling LA; Cowan K; Wendel K; Burke PJ
Blood; 1994 Jan; 83(2):517-30. PubMed ID: 7904487
[TBL] [Abstract][Full Text] [Related]
13. Concentration and timing dependence of lethality enhancement between topotecan, a topoisomerase I inhibitor, and ionizing radiation.
Lamond JP; Wang M; Kinsella TJ; Boothman DA
Int J Radiat Oncol Biol Phys; 1996 Sep; 36(2):361-8. PubMed ID: 8892461
[TBL] [Abstract][Full Text] [Related]
14. The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux.
Erlichman C; Boerner SA; Hallgren CG; Spieker R; Wang XY; James CD; Scheffer GL; Maliepaard M; Ross DD; Bible KC; Kaufmann SH
Cancer Res; 2001 Jan; 61(2):739-48. PubMed ID: 11212277
[TBL] [Abstract][Full Text] [Related]
15. Protracted intermittent schedule of topotecan in children with refractory acute leukemia: a pediatric oncology group study.
Furman WL; Stewart CF; Kirstein M; Kepner JL; Bernstein ML; Kung F; Vietti TJ; Steuber CP; Becton DL; Baruchel S; Pratt C
J Clin Oncol; 2002 Mar; 20(6):1617-24. PubMed ID: 11896112
[TBL] [Abstract][Full Text] [Related]
16. Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation in patients with refractory or relapsed acute leukemia.
Vey N; Kantarjian H; Tran H; Beran M; O'Brien S; Bivins C; Giles F; Cortes J; Cheson B; Arbuck S; Estey E
Ann Oncol; 1999 May; 10(5):577-83. PubMed ID: 10416008
[TBL] [Abstract][Full Text] [Related]
17. Phase I clinical and laboratory evaluation of topotecan and cytarabine in patients with acute leukemia.
Seiter K; Feldman EJ; Halicka HD; Traganos F; Darzynkiewicz Z; Lake D; Ahmed T
J Clin Oncol; 1997 Jan; 15(1):44-51. PubMed ID: 8996123
[TBL] [Abstract][Full Text] [Related]
18. Escalating systemic exposure of continuous infusion topotecan in children with recurrent acute leukemia.
Furman WL; Baker SD; Pratt CB; Rivera GK; Evans WE; Stewart CF
J Clin Oncol; 1996 May; 14(5):1504-11. PubMed ID: 8622064
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of CI-973, a platinum analogue, in refractory or relapsed acute leukemia.
Kantarjian HM; Beran M; O'Brien S; Robertson L; Siddik Z; Yoshida M; Yang LY; Rios MB; Keating MJ; Meyer M
Leukemia; 1996 Mar; 10(3):396-401. PubMed ID: 8642853
[TBL] [Abstract][Full Text] [Related]
20. Phase I and pharmacodynamic study of taxol in refractory acute leukemias.
Rowinsky EK; Burke PJ; Karp JE; Tucker RW; Ettinger DS; Donehower RC
Cancer Res; 1989 Aug; 49(16):4640-7. PubMed ID: 2568175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]